KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $191.8 million.

  • Arbutus Biopharma's Shares Outstanding (Diluted Average) rose 147.19% to $191.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.8 million, marking a year-over-year increase of 147.19%. This contributed to the annual value of $185.6 million for FY2024, which is 1183.93% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Shares Outstanding (Diluted Average) is $191.8 million, which was up 147.19% from $192.4 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Shares Outstanding (Diluted Average) high stood at $192.4 million for Q2 2025, and its period low was $93.4 million during Q1 2021.
  • Over the past 5 years, Arbutus Biopharma's median Shares Outstanding (Diluted Average) value was $166.0 million (recorded in 2023), while the average stood at $156.4 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 5885.84% in 2022, then soared by 147.19% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Shares Outstanding (Diluted Average) stood at $106.2 million in 2021, then soared by 42.07% to $150.9 million in 2022, then rose by 9.95% to $166.0 million in 2023, then increased by 11.84% to $185.6 million in 2024, then rose by 3.32% to $191.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $191.8 million for Q3 2025, versus $192.4 million for Q2 2025 and $190.7 million for Q1 2025.